Journal of Contemporary Psychotherapy

, Volume 36, Issue 4, pp 183–190 | Cite as

Panacea or Placebo: The Historical Quest for Medications to Treat Depression

Original Paper


Background: Over the years, there have been many advances in contemporary medicine and the ability to treat depression with medications. However, some innovative practices in medical treatments appear less than ideal when viewed from a historical perspective. Aims: It is important for health care professionals to appreciate the risks and limitations of a biological approach to an emotional disorder. Conclusions: If professionals can learn from past mistakes, they can better evaluate the merits of contemporary treatments.


Depression Treatment Antidepressant 


  1. Agosti, V., Stewart, J. W., Quitkin, F. M., & Ocepek-Welikson, K. (1993). How symptomatic do depressed patients remain after benefiting from medication treatment? Comprehensive Psychiatry, 34, 182–186.PubMedCrossRefGoogle Scholar
  2. Allison, H. E. (1897). Simple melancholia and its treatment. Medical Record, 51, 39–41.Google Scholar
  3. Altschule, M. D., & Tillotson, K. J. (1948). The use of testosterone in the treatment of depressions. New England Journal of Medicine, 239, 1036–1038.PubMedCrossRefGoogle Scholar
  4. Ambrosini, P. J., Bianchi, M. D., Rabinovich, H., & Elia, J. (1993). Antidepressant treatments in children and adolescents: I. Affective disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1–6.PubMedCrossRefGoogle Scholar
  5. American Psychiatric Association. (2000). Practice guidelines for the treatment of patients with Major Depressive Disorder (Revision). American Journal of Psychiatry, 157(supplement), 1–45.Google Scholar
  6. Antonuccio, D. O., Danton, W. G., & DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3–14.PubMedCrossRefGoogle Scholar
  7. Blake, J. E., & Hamilton, A. M. (1880). A preliminary report upon the use of dilute nitrous oxide gas in the treatment of melancholia and nervous exhaustion. Lancet, 17, 118.Google Scholar
  8. Bos, C., & Lehmann, H. (1950). Studies on psychiatric patients undergoing nitrous oxide treatments. Journal of Mental Science, 96, 509–513.PubMedGoogle Scholar
  9. Bowman, K. M., & Bender, L. (1932). The treatment of involution melancholia with ovarian hormone. American Journal of Psychiatry, 11, 869–893.Google Scholar
  10. Brigham, A. (1842). Medical treatment of insanity. Boston Medical and Surgical Journal, 26, 389–390.Google Scholar
  11. Brigham, A. (1846). The medical treatment of insanity. American Journal of Insanity, 3, 353–358.Google Scholar
  12. Brugha, T., Bebbington, P., MacCarthy, B., Surt, E., & Wykes, T. (1992). Antidepressants may not assist recovery in practice: A naturalistic prospective survey. Acta Psychiatrica Scandinavica, 86, 5–11.PubMedGoogle Scholar
  13. Byrne, S. E., & Rothschild, A. J. (1998). Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. Journal of Clinical Psychiatry, 59, 279–288.PubMedGoogle Scholar
  14. Cheadle, W. B. (1894). The clinical uses of opium. The Clinical Journal, 4, 345–351.Google Scholar
  15. Courtenay, E. M. (1872). The use of opium in the treatment of melancholia. West Riding Lunatic Asylum Medical Reports, 2, 254–277.Google Scholar
  16. Danziger, L. (1942). Estrogen therapy of agitated depressions associated with the menopause. Archives of Neurology and Psychiatry, 47, 305–313.Google Scholar
  17. Danziger, L., & Blank, H. R. (1942). Androgen therapy of agitated depressions in the male. Medical Annals of the District of Columbia, 11, 181–183.Google Scholar
  18. Danziger, L., Schroeder, H. T., & Unger, A. A. (1944). Androgen therapy for involutional melancholia. Archives of Neurology and Psychiatry, 51, 457–461.Google Scholar
  19. Demyttenaere, K., Enzlin, P., Dewe, W., Boulanger, B., DeBie, J., Troyer, W., & Mesters, P. (2001). Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. Journal of Clinical Psychiatry, 62(Suppl 22), 30–33.PubMedGoogle Scholar
  20. Denber, H., & Merlis, S. (1954). A note on some therapeutic implications of the mescaline-induced state. Psychiatric Quarterly, 28, 635–640.CrossRefGoogle Scholar
  21. Dording, C. (2000). Antidepressant augmentation and combinations. Psychiatric Clinics of North America, 23, 743–755.PubMedCrossRefGoogle Scholar
  22. Dubois, P. (1905). The psychic treatment of nervous disorders. New York: Funk & Wagnalls.Google Scholar
  23. Fava, G. (2002). Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychotherapy and Psychosomatics, 71, 127–132.CrossRefGoogle Scholar
  24. Fava, G. A., Savron, G., Grandi, S., & Rafanelli, C. (1997). Cognitive-behavioral management of drug-resistant major depressive disorder. Journal of Clinical Psychiatry, 58, 278–282.PubMedGoogle Scholar
  25. Gray, J. P. (1859). On the use of cannabis indica in the treatment of insanity. American Journal of Insanity, 16, 80–89.Google Scholar
  26. Greenberg, R. P., & Fisher, S. (1997). Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions. In S. Fisher & R. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 115–172). New York: Wiley.Google Scholar
  27. Greisinger, W. (1965). Mental pathology and therapeutics. New York: Hafner. (original work published 1867).Google Scholar
  28. Heiman, M. (1942). On the use of strychnine in the curare-aided metrazol treatment of psychoses. American Journal of Psychiatry, 99, 706–711.Google Scholar
  29. Hirschfeld, R. M. (2001). Clinical importance of long-term antidepressant treatment. British Journal of Psychiatry, 179(suppl.), s4–s8.CrossRefGoogle Scholar
  30. Hughes, C. H. (1886). An outline brief in the management of melancholia. Alienist and Neurologist, 7, 217–236.Google Scholar
  31. Joffe, R., Sokolov, S., & Streiner, D. (1996). Antidepressant treatment of depression: A metaanalysis. Canadian Journal of Psychiatry, 41, 613–616.Google Scholar
  32. Jones, H. L. (1885). Notes on cannabis indica as a narcotic. The Practitioner, 15, 251.Google Scholar
  33. Keller, M., & Boland, R. (1998). Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar depression. Biological Psychiatry, 44, 348–360.PubMedCrossRefGoogle Scholar
  34. Kessler, R., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K., Rush, A. J., Walters, E., & Wang, P. (2003). The epidemiology of Major Depressive Disorder. Journal of the American Medical Association, 289, 3095–3105.PubMedCrossRefGoogle Scholar
  35. Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment, 1, 1–18.Google Scholar
  36. Kitchen, D. H. (1873). Conium in the treatment of insanity. American Journal of Insanity, 29, 457–480.Google Scholar
  37. Kuh, S. (1918). Melancholia. Journal of Nervous and Mental Disease, 47, 411–417.CrossRefGoogle Scholar
  38. Kupfer, D. J. (1992). Maintenance treatment in recurrent depression: Current and future directions. British Journal of Psychiatry, 161, 309–316.PubMedGoogle Scholar
  39. Lehmann, H. (1960). Combined pharmaco-fever treatment with imipramine (Tofranil) and typhoid vaccine in the management of depressive conditions. American Journal of Psychiatry, 117, 356–358.PubMedGoogle Scholar
  40. Lehmann, H., & Bos, C. (1947). The advantages of nitrous oxide inhalation in psychiatric treatment. American Journal of Psychiatry, 104, 164–170.PubMedGoogle Scholar
  41. Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., & Abrams, M. (2002). Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry, 159, 122–129.PubMedCrossRefGoogle Scholar
  42. Lipowski, Z. (1989). Psychiatry: Mindless or brainless, both or neither? Canadian Journal of Psychiatry, 34, 249–254.Google Scholar
  43. Masand, P., Anand, V., & Tanquary, J. (1998). Psychostimulant augmentation of second generation antidepressants: A case series. Depression and Anxiety, 7, 89–91.PubMedCrossRefGoogle Scholar
  44. Maudsley, H. (1869). On opium in the treatment of insanity. The Practitioner, 2, 1–8.Google Scholar
  45. Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials. Journal of Nervous and Mental Disease, 189, 288–295.PubMedCrossRefGoogle Scholar
  46. Moncrieff, J. (2002). The antidepressant debate. British Journal of Psychiatry, 180, 193–194.PubMedCrossRefGoogle Scholar
  47. Moncrieff, J., Wessely, S., & Hardy, R. (1998). Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry, 172, 227–231.PubMedCrossRefGoogle Scholar
  48. Monro, A. B., & Conitzer, H. (1950). A comparison of desoxyephedrine (methedrine) and electroshock in the treatment of depression. Journal of Mental Science, 96, 1037–1042.PubMedGoogle Scholar
  49. Nestler, E. (1998). Antidepressant treatments in the 21st century. Biological Psychiatry, 44, 526–533.PubMedCrossRefGoogle Scholar
  50. Noble, D. (1857). On the use of opium in the treatment of insanity. Asylum Journal, 4, 111–118.Google Scholar
  51. Nuckolls, L. J. (1897). Treatment of melancholia with opium. Medical Record, 51, 880.Google Scholar
  52. Olfson, M., Marcus, S. C., Druss, B., Elinson, L., Tanielian, T., & Pincus, H. A. (2002). National trends in the outpatient treatment of depression. Journal of the American Medical Association, 287, 203–209.PubMedCrossRefGoogle Scholar
  53. Palmer, H. D., Hastings, D. W., & Sherman, S. H. (1941). Therapy in involutional melancholia. American Journal of Psychiatry, 97, 1086–1115.Google Scholar
  54. Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2004). Combined pharmacotherapy and psychological treatment for depression. Archives of General Psychiatry, 61(7), 714–719.PubMedCrossRefGoogle Scholar
  55. Parker, G., Roy, K., Wilhelm, K., & Mitchell, P. (2001). Assessing the comparative effectiveness of antidepressant therapies: A prospective clinical practice study. Journal of Clinical Psychiatry, 62, 117–125.PubMedCrossRefGoogle Scholar
  56. Parker, C. S., & Wrigley, F. (1950). Synthetic cannabis preparations in psychiatry. Journal of Mental Science, 96, 276–279.Google Scholar
  57. Persons, J. B., Thase, M. E., & Crits-Christoph, P. (1996). The role of psychotherapy in the treatment of depression: Review of two practice guidelines. Archives of General Psychiatry, 53, 283–290.PubMedGoogle Scholar
  58. Pinel, P. (1806). A treatise on insanity. London: Sheffield.Google Scholar
  59. Pope, H., Cohane, G., Kanayama, G., Siegel, A., & Hudson, J. (2003). Testosterone gel supplementation for men with refractory depression: A randomized placebo-controlled trial. American Journal of Psychiatry, 160, 105–111.PubMedCrossRefGoogle Scholar
  60. Posternak, M., & Miller, I. (2001). Untreated short-term course of major depression. Journal of Affective Disorders, 66, 139–146.PubMedCrossRefGoogle Scholar
  61. Posternak, M., Zimmerman, M., Keitner, G., & Miller, I. (2002). A reevaluation of the exclusion criteria used in antidepressant efficacy trials. American Journal of Psychiatry, 159, 191–200.PubMedCrossRefGoogle Scholar
  62. Procopio, M. (2005). The multiple outcomes bias in antidepressant research. Medical Hypotheses, 65(2), 395–399.PubMedCrossRefGoogle Scholar
  63. Reimherr, F., Strong, R., Marchant, B., Hedges, D., & Wender, P. (2001). Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. Journal of Clinical Psychiatry, 62(suppl 22), 16–23.PubMedGoogle Scholar
  64. Reynolds, J. R. (1890). Therapeutical uses and toxic effects of cannabis indica. Lancet, 1, 637–638.CrossRefGoogle Scholar
  65. Richardson, A. B. (1891). Simple melancholia and its treatment. Medical News, 58, 685–689.Google Scholar
  66. Rudolf, G. (1949). The treatment of depression with desoxyephedrine (methedrine). Journal of Mental Science, 95, 920–929.Google Scholar
  67. Rudolf, G. (1955). Treatment of depression with sympathomimetic preparations. The Practitioner, 174, 180–183.Google Scholar
  68. Rudolf, G. (1956). The treatment of depression with methylamphetamine. Journal of Mental Science, 102, 358–363.Google Scholar
  69. Rush, B. (1812). Medical inquiries and observations upon the diseases of the mind. Philadelphia: Kimer & Richardson.Google Scholar
  70. Russell, I. (1881). Melancholia. Alienist and Neurologist, 2, 195–207.Google Scholar
  71. Safer, D. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583–592.PubMedCrossRefGoogle Scholar
  72. Sandison, R., Spencer, A., & Whitelaw, J. (1954). The therapeutic value of Lysergic Acid Diethylamide in mental illness. Journal of Mental Science, 100, 491–507.PubMedGoogle Scholar
  73. Savage, C. (1952). Lysergic Acid Diethylamide (LSD-25): A clinical-psychological study. American Journal of Psychiatry, 108, 896–900.PubMedGoogle Scholar
  74. Smith, G., Clarke, D., Handrinos, D., & Trauer, T. (2002). Adverse reactions to antidepressants in consultation-liaison psychiatry inpatients. Psychosomatics, 43, 228–233.PubMedCrossRefGoogle Scholar
  75. Smith, W. (1912). On the use of brain extract in the treatment of various forms of insanity. British Medical Journal, 2, 1451–1454.Google Scholar
  76. Sommers-Flanagan, J., & Sommers-Flanagan, R. (1996). Efficacy of antidepressant medication with depressed youth: What psychologists should know. Professional Psychology: Research and Practice, 27, 145–153.CrossRefGoogle Scholar
  77. Stockings, G. T. (1947). A new euphoriant for depressive mental states. British Medical Journal, 1, 918–922.CrossRefPubMedGoogle Scholar
  78. Stockton, G. (1901). Melancholia and its treatment. Philadelphia Medical Journal, 8, 571–573.Google Scholar
  79. Swindle, R. W., Cronkite, R. C., & Moos, R. H. (1998). Risk factors for sustained nonremission of depressive symptoms: A 4-year follow-up. Journal of Nervous and Mental Disease, 186, 462–469.PubMedCrossRefGoogle Scholar
  80. Thase, M. E., & Kupfer, D. J. (1996). Recent developments in the pharmacotherapy of mood disorders. Journal of Consulting and Clinical Psychology, 64, 646–659.PubMedCrossRefGoogle Scholar
  81. Thase, M. E., & Rush, A. J. (1997). When at first you don't succeed: Sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry, 58(Suppl 13), 23–29.PubMedGoogle Scholar
  82. Wells, K. B., Burnham, A., Rogers, W., Hays, W., & Camp, P. (1992). The course of depression in adult outpatients: Results from the Medical Outcomes Study. Archives of General Psychiatry, 49, 788–794.PubMedGoogle Scholar
  83. Whittington, C., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression. Lancet, 363, 1341–1345.PubMedCrossRefGoogle Scholar
  84. Woodward, S. (1850). Observations on the medical treatment of insanity. American Journal of Insanity, 7, 1–34.Google Scholar
  85. Young, G. (1963). A treatise on opium, founded upon practical observation. Reprinted in R. Hunter & I. MacAlpine (Eds.), Three hundred years of psychiatry: 1535–1860, (pp. 395–398). New York: Oxford University Press. (original work published 1753).Google Scholar
  86. Ziehen, T. (1897). The diagnosis and treatment of melancholia. American Journal of Insanity, 54, 579–587.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of PsychologyCase Western Reserve UniversityClevelandUSA

Personalised recommendations